Supplementary_table_2 – Supplemental material for KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC Marika Cinausero Noemi Laprovitera Giovanna De Maglio Lorenzo Gerratana Mattia Riefolo Marianna Macerelli Michelangelo Fiorentino Elisa Porcellini Vanessa Buoro Francesco Gelsomino Anna Squadrilli Gianpiero Fasola Massimo Negrini Marcello Tiseo Manuela Ferracin Andrea Ardizzoni 10.25384/SAGE.10315562.v1 https://sage.figshare.com/articles/journal_contribution/Supplementary_table_2_Supplemental_material_for_KRAS_and_ERBB-family_genetic_alterations_affect_response_to_PD-1_inhibitors_in_metastatic_nonsquamous_NSCLC/10315562 <p>Supplemental material, Supplementary_table_2 for KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC by Marika Cinausero, Noemi Laprovitera, Giovanna De Maglio, Lorenzo Gerratana, Mattia Riefolo, Marianna Macerelli, Michelangelo Fiorentino, Elisa Porcellini, Vanessa Buoro, Francesco Gelsomino, Anna Squadrilli, Gianpiero Fasola, Massimo Negrini, Marcello Tiseo, Manuela Ferracin and Andrea Ardizzoni in Therapeutic Advances in Medical Oncology</p> 2019-11-16 13:06:44 anti-PD-1 immunotherapy nivolumab non-small cell lung cancer pembrolizumab